Abstract
Introduction
Dendritic cells (DCs) have the ability to capture, process and present antigens within the context of MHC-I and -II to CD8 + and CD4 + T lymphocytes, respectively, thereby initiating and maintaining adaptive immune responses [1] . DCs can present exogenous-derived antigens on MHC-I in a process known as cross-presentation. This phenomenon holds great interest, since it can directly contribute to the induction of anti-tumor CD8 + T cells responses. Preferred strategies for DC targeting as cancer immunotherapy are based on the delivery of tumor antigens to DCs in-vivo. This requires modification of antigens to allow recognition by specific DCs resulting in antigen internalization. Promising targets are the C-type lectin receptors (CLRs), which are expressed by distinct DCs and known to internalize antigen and induce T cell responses, like DEC-205 [2] [3] [4] and DC-specific ICAM-3-grabbing non-integrin (DC-SIGN) [5;6] . Most studies use monoclonal antibodies to target DC subsets [2;3;7-9] . However, antibodies can induce adverse immunogenic effects that obstruct the induction of successful antitumor responses [10] . Using natural glycan ligands for CLRs would be a more versatile approach, since glycans are expressed throughout the body and therefore poorly immunogenic. It has been demonstrated that the modification of antigens using DC-SIGN-binding glycans resulted in efficient antigen internalization and increased T cell responses [5;6;11;12] , making DC-SIGN an attractive receptor for targeting. Ligands for DC-SIGN comprise of high-mannose oligosaccharides and Lewis-type epitopes, like Lewis X (Le X ) [13] . DC-SIGN is highly expressed on in-vitro generated monocytederived DC (moDCs), on DCs at mucosal sites, as well as in skin and lymph nodes [14] . The main populations of DCs that can be found in the human skin are the CD1a high Langerin + Langerhans cells (LCs) present in the epidermis, the CD1a + /CD1c + DC subset present in the dermis and the CD14 + dermal DCs (dDCs) [15] [16] [17] . In humans, DC-SIGN is primarily expressed by CD14 + dDCs. LCs were shown to efficiently prime CD8 + T cells, whereas CD14 + dDCs induced the generation of follicular T helper cells [16] . CD1c + dDCs have recently been described as the functional equivalents of mouse CD11b + DCs and posses Th17-polarizing capacities [18] . Additionally, it has been shown that human CD1a
+ dDCs stimulated CD4 + T cell proliferation and primed CD8 + T cells [19] . Whether in-situ DC-SIGN targeting influences the T cell priming capacities of the skin DC subsets is currently not known. Here, we used glycan-modified liposomes to target DC-SIGN + DCs intradermally to induce tumor-specific T cell responses. Liposomes are spherical nanoparticles, which can encapsulate large quantities of molecules, like anti-tumor peptides. The human skin model resembles the physiological in-vivo situation, allowing the examination of targeting specificity of vaccine formulation to DC subsets within the skin tissue, as well as the potential to alter the cross-presenting capacity of skin DC subsets to induce tumor-specific T cell responses. 
Results

Le
X -and αDC-SIGN-modified liposomes are internalized by DC-SIGN As previously reported, Le X can bind with high affinity to DC-SIGN [13] . We conjugated Le X to liposomes in order to target DC-SIGN + DCs. As a positive control, we also modified liposomes with anti-DC-SIGN antibodies (αDC-SIGN). Indeed, DC-SIGN-Fc constructs bound to the Le X -and αDC-SIGN-liposomes coated to ELISA plates (Fig. 1a) . Modification of liposomes with Le X or αDC-SIGN resulted in enhanced binding to DC-SIGN and an increased internalization of modified liposomes by moDCs as measured by an increase in the MFI (Fig. 1b) . Both the percentage of DiD Liposome modification 
DCs and the MFI increased upon modification of the liposomes with Le
X glycans or αDC-SIGN antibodies ( Figure S1 ). Le X -and αDC-SIGN-modified liposomes were equally well internalized by DC-SIGN + moDCs, indicating that glycans are as efficient to target DC-SIGN as antibodies. Besides DC-SIGN, moDCs do express other CLRs, like the mannose receptor (MR), DCIR and MGL (Fig.1c) . To exclude that these CLRs contributed to the liposomal internalization, we incubated moDCs with Le X -modified liposomes in the presence of neutralizing monoclonal antibodies (mAbs) against MR, MGL, DCIR and langerin. As shown in figure 1d , internalization of Le X -and αDC-SIGN-modified liposomes was solely mediated through DC-SIGN, since addition of neutralizing antibodies directed against the other CLRs did not hamper liposomal internalization. Neutralizing antibodies against DC-SIGN completely abrogated the internalization of Le x -modified liposomes (Fig. 1d) .
DC-SIGN is mainly expressed by CD14
+ dDCs We analyzed DC-SIGN expression on the three main migratory DCs subsets present in the human skin. As shown in Fig. 2 , DC-SIGN is mainly expressed by the CD14 + dDCs. Moderate expression of DC-SIGN was found on the CD1a + dDCs, whereas human LCs do not express DC-SIGN (Fig. 2) .
Intradermal injection of GM-CSF and IL-4 mobilizes and matures skin DCs
We investigated the potential of intradermally injected TLR ligands to mobilize and mature skin DCs, since these characteristics influence T cell activation. We tested a panel of TLR ligands (the TLR3 ligand pI:C; the TLR4 ligand LPS and the TLR7/8 ligand R848) in the skin and analyzed the subset distribution and maturation state of emigrated CD14 + and CD1a + dDCs. We also injected GM-CSF and IL-4 (GM/4), since administration of GM/4 has been shown to enhance migration of the phenotypically more mature CD1a + dDCs [20;21] . Indeed, injection of GM/4 resulted in higher levels of migrated HLA-DR + DCs as compared to injection of medium or the TLR ligands (Fig. 3a) . Furthermore, GM/4 significantly reduced the percentage of migrated CD14 + DCs from 33% to 8%, whereas the percentage of migrated CD1a + dDCs increased from 43% to 75% (Fig. 3b) compared to medium (Fig. 3c, left panel) . Rather, the decreased percentage of CD14 + dDCs was caused by an increase in the absolute numbers of migrated CD1a + dDCs (Fig. 3c, right panel) . Besides, intradermal injection of GM/4 increased the expression of DC-SIGN by CD14 + and CD1a + dDCs, which was not observed upon injection of TLR ligands (Fig.  3d+e) . GM-CSF, in the absence of IL-4, was found to be the main factor responsible for the upregulation of DC-SIGN during in-vitro moDCs generation [22] . To determine whether the upregulation of DC-SIGN on skin DCs was induced by GM-CSF and/or IL-4, we administered IL-4, GM-CSF or the combination intradermally and analyzed DC-SIGN expression. GM-CSF alone did increase DC-SIGN expression on both CD14 + and CD1a
+ dDCs (Fig. 3f) . Again, CD14 + dDCs expressed higher levels of DC-SIGN as (Fig. 4a) . Moreover, co-injection of neutralizing antibodies against DC-SIGN abrogated the internalization of Le X -and αDC-SIGNmodified liposomes by dDCs (Fig. 4a) , indicative of DC-SIGN-mediated internalization. Since high expression of DC-SIGN is particularly found on CD14
+ dDCs, we analyzed liposome internalization on the CD14 + and CD1a + dDCs separately. Consistent with the DC-SIGN expression in human skin, highest internalization of DC-SIGN-targeting liposomes was detected in the CD14 + dDCs (Fig. 4b ). In addition, 45% and 68% of the CD14 + dDCs had taken up Le X -or αDC-SIGN-modified liposomes respectively, compared to 28% and 51% of the CD1a + dDCs ( Figure S3A ). Although the percentages of liposome + cells were highest in the CD14 + dDC subset, the main difference between the two dDC subsets was observed in the amount of liposomes taken up (measured by the MFI of DiD). The MFI measured on the C14 + dDCs after internalization of Le X -or αDC-SIGN-modified liposomes was 363 and 487, respectively, whereas the MFI measured on the CD1a + dDCs after internalization of Le X -or αDC-SIGN-modified liposomes was 101 and 124, respectively ( Figure 4B ). Again, neutralizing antibodies against DC-SIGN decreased the internalization of modified liposomes (Fig. 4b) .
In-situ skin targeting of DC-SIGN using Le X -modified liposomes enhances antigen cross-presentation by CD14
+ dDCs Liposomal internalization via DC-SIGN may facilitate antigen cross-presentation to CD8 + T cells, since DC-SIGN can route antigen to MHC-I loading compartments [5;23] . Therefore, Le X -modified liposomes containing a 15-aa long MART-1 peptide or a 9-aa long Gp100 peptide were generated and injected intradermally in the presence of GM/4. Since we did not observe a difference between the Le X -and αDC-SIGN-modified liposomes in the antigen presentation assays after internalization by moDCs ( Figure S4 ), we focused on the comparison between unmodified and Le Xmodified liposomes in experiments using human skin. Migratory DCs were tested in antigen presentation assays using a CD8 + T cell clone specific for MART-1 26-35(27L) or Gp100 280-288 . Indeed, enhanced dose-dependent cross-presentation of the MART-1 peptide to the CD8 + T cells was observed when the liposomes were coated with Le X and targeted to DC-SIGN + dDCs, as measured by significantly increased production of IFN-γ (Fig.5a ).
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Since we observed the highest internalization of the liposomes in the CD14 + dDCs (Fig. 4b) and this subset has been described to lack the potential to cross-present antigens [16;24] , we determined which dermal DC subpopulation contributed to the observed effects on antigen cross-presentation. Using MACS-isolation, we separated migrated CD14 + dDCs from the CD1a + dDCs and incubated the DC subsets with Gp100 peptide-containing liposomes and GM/4, where after dDCs were cocultured with Gp100-specific CD8 + T cells. MACS isolation resulted in an enrichment of separated CD1a + and CD14 + dDCs (Fig. S5) . We also analyzed CCR7 expression on the purified subsets (Fig. S6 ). Highest expression of CCR7 was found on the CD1a + dDCs, which is in line with previously reported data [24] . However, the CD14 + dDCs did also express CCR7. With regard to CD8 + T cell activation, Gp100-specific CD8 + T cell reactivity was enhanced upon co-culture with DC-SIGN-targeted CD14 + dDCs but not with similarly targeted CD1a + dDCs, providing evidence that primarily the CD14 + dDCs are capable to cross-present and induce CD8 + T cell activation after antigen internalization through DC-SIGN (Fig. 5b) . To exclude the possibility of an intrinsic difference in cross-presenting capacity between the DC subsets, we loaded the CD14 + and CD1a + dDCs with the 9 aa Gp100 peptide, which can directly bind the MHC-I, and co-cultured the pulsed cells with the Gp100-specific T cell clone. We could not observe a difference between the two subsets in their capacity to activate the CD8 + T cells, showing that both dDC subsets were equally potent to crosspresent antigen (Fig. S7) . Consequently, the difference in cross-presenting capacity between the CD14 + and CD1a + dDCs after liposomal internalization are likely caused by the targeting through DC-SIGN. 
Discussion
Here we demonstrate that Le x -modified liposomes target antigens to DC-SIGNexpressing DCs within the human skin. Moreover, simultaneous administration of GM/4 enhanced the DC-SIGN expression, facilitating a DC-SIGN-mediated internalization of Le X -modified liposomes preferentially by CD14 + dDCs and subsequent cross-presentation to CD8 + T cells. Using the human skin explant model, we were able to assess the internalization and fate of antigen-encapsulated liposomes in-situ. This model simulates the migration of DCs towards the draining lymph nodes, which is the location where naive antigenspecific T cells will be primed and activated. Lymph node migration is directed by CCL19 and CCL21 signaling through CCR7. Recently, it was shown that CD14 + dDCs did not express CCR7, even upon stimulation with LPS, IL-1β and TNF-α. However, spontaneous migration of the CD14 + dDCs from the skin was observed, suggesting that CD14 + migratory dDCs exited the skin without entering the lymphatics [24] . Here, we have demonstrated that CD14 + dDCs do also express CCR7 after spontaneous migration, indicating that these cells might migrate to draining lymph nodes. Definitive prove of the capacity of CD14 + dDCs to migrate to the lymph nodes can not be tested in the human skin explant model and is still a topic that needs to addressed. In addition, antigen-loaded and matured skin-resident dDCs could also add to the anti-tumor responses induced by the vaccine by providing local antigenspecific signals that stimulate effector T cells, especially at an immunosuppressive tumor site. + skin was injected intradermally with MART-1 containing liposomes resuspended in medium + GM/4. Emigrated DCs were harvested after 2 days and co-cultured with an HLA-A2-resricted, MART-1 specific CD8
+ T clone at a ratio of 1:5. After 24 h, IFN-γ was measured using ELISA. n=3, mean ± SEM, *p<0.05 and **p<0.01, using a two-way ANOVA. B. MACS-sorted CD14 + and CD1a + dDCs were allowed to internalize GP100-containing liposomes and co-cultured with an HLA-A2-resricted, GP100 specific CD8 + T clone at a ratio of 1:5. After 24 h, IFN-γ was analyzed using ELISA. N=3, mean ± SEM, **p<0.01 as measured by a two-way ANOVA. + dDCs induced higher activation of antigen-specific effector CD8 + T cells than CD1a + dDCs, providing evidence that CD14 + dDCs can cross-present efficiently after DC-SIGN-mediated internalization of the antigen. The apparent discrepancy of our observation concerning the potential of CD14 + dDCs to cross-present antigen to those of others may be dependent on the method to induce cross-presentation. In our study we have analyzed the capacity of DCs to cross-present antigens that were specifically internalized via DC-SIGN. Others have contributed the weak cross-presenting potential of the CD14 + dDCs based on their capacity to cross-present soluble peptides, apoptotic cells or untargeted antigens [17;17;25] . It is possible that the DC-SIGN-mediated uptake of antigen favors efficient antigen routing to MHC-I processing and loading compartments. DC-SIGN targeting thereby overrules the poor cross-presenting potential of untargeted antigens by CD14
+ by affecting the intracellular antigen routing. This is supported by data of our own group and others [5;6;26] , in which targeting of antigen to human DC-SIGN was approximately 100-fold more efficient in inducing T cell responses than soluble antigens. Another possible explanation may be the intradermal injection of GM/4. We show that GM/4 resulted in an increased expression of DC-SIGN on both the migrated CD1a + and CD14 + dDC subsets, although the levels were lower on the CD1a + dDCs (Figure 3f ). It is currently unknown whether GM/4 can induce higher expression of DC-SIGN on DC subsets already positive for DC-SIGN or whether it may induce denovo expression on cells present in the intact skin microenvironment. From in-vitro studies using blood monocytes, it is known that GM-CSF and IL-4 induce the differentiation from DC-SIGN neg CD14 + monocytes to CD1a + moDCs with a high expression of DC-SIGN [27] . Intradermal administration of GM/4 to the skin not only alter he expression of DC-SIGN, it also resulted in the increased migration of the phenotypically more mature CD1a + dDCs [20] . Concluding, conjugation of Le X or αDC-SIGN antibodies to liposomes facilitated in-
cells results in enhanced CD8
+ T cell responses situ targeting of DC-SIGN + DCs after intradermal vaccination, resulting in the efficient delivery of the liposomal cargo to DC-SIGN + DCs. Furthermore, DC-SIGN-mediated internalization of Le X -modified liposomes resulted in enhanced antigen crosspresentation by GM/4-stimulated dDCs and subsequently increased antigen specific CD8 + T cell responses, mainly through CD14 + dDCs. Therefore, the combined administration of glycoliposomes with GM/4 as adjuvant represent an efficient system to specifically deliver antigens to DC subsets for the induction of CD8 T cell responses and should be considered as a promising strategy for the development of targeted anti-tumor immunotherapy.
Materials and methods
DC isolation from human skin explants LCs and CD14
+ and CD1a + dDCs were isolated from human skin derived from abdominal resections from healthy donors (Bergman Clinics, Bilthoven, The Netherlands), which were obtained with informed consent within 24h after plastic surgery. Skin was incubated with dispase (Roche, Basel, Switzerland) for 16 h at 4°C followed by the separation of epidermal and dermal sheets using tweezers. Epidermal sheets were cut in pieces and incubated for 30 min at 37°C in PBS containing trypsin and DNase, where-after the cells were run over a 100 μm cell strainer to obtain a single cell suspension. LCs are purified using a Ficoll gradient resulting in approximately 90% pure LCs. To isolate dDCs, dermal sheets were cut in small pieces and incubated in collagenase A, dispase and DNase for 2 h, 37°C. A single cell suspension was obtained by putting the suspension over a 100 μm cell strainer. Where indicated, migrated dDCs and LCs were MACS-sorted using CD1a and CD14 microbeads (MACS, Miltenyi Biotec) or DC subsets were FACS-sorted using a MoFlo cell sorter (Beckman Coulter) and fluorescent antibodies directed against HLA-DR, CD1a and CD14.
Intradermal injection and culture of skin biopsies
Liposomes were diluted in serum-free medium (IMDM) and injected intradermally as described previously [21] . Biopsies were taken after injection using a 6 mm biopsy punch (Microtek, Zutphen, The Netherlands) and cultured in a 48 wells plate containing 1 ml of IMDM supplemented with 10% FCS, 10 μg/ml gentamycin, penicillin and L-glutamine for 48 h, 37°C, 5% CO 2 . In each experiment, 10-15 biopsies were taken per condition. After 48 h of culture, the biopsies were discarded and emigrated DCs were harvested and used for experiments.
Phenotypic analysis of crawl-out cells
Analysis of emigrated cells was performed by flow cytometry as previously described [21] . Fluochrome-conjugated mAbs used were specific for CD1a, CD14, CD70, CD86, DC-SIGN, HLA-DR (BD, San Jose, CA, USA), HLA-ABC (ImmunoTools, Friesoythe, Germany), CD83 (Beckman Coulter Immunotech), CCR7 (R&D Systems) or isotypematched control mAbs (BD, San Jose, CA, USA). For the intracellular DC-SIGN staining were the cells treated with 0.1% saponin for 30 min at RT, washed and consequently stained with DC-SIGN, CD1a and CD14.
Real-Time PCR FACS-sorted CD14
+ dDCs, CD1a + dDCs and LCs were pooled from at least 4 human skin donors to obtain high enough numbers for analysis. Pooled cells were lysed and mRNA was isolated using an mRNA Capture kit (Roche, Basel, Switzerland). cDNA was synthesized using the Reverse Transcription System kit (Promega, Madison, WI, USA) following manufacturer's guidelines. Oligonucleotides were designed using the Primer Express 2.0 software (Applied Biosystems) and synthesized by Invitrogen Life Technologies (Invitrogen, CA, USA). Real-Time PCR analysis was performed as previously described using the SYBR Green method in an ABI 7900HT sequence detection system (Applied Biosystems) [28] . GAPDH was used as an endogenous reference gene.
Liposome preparation
Liposomes were prepared as previously described [29] . The MART-1 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] or Gp100 [280] [281] [282] [283] [284] [285] [286] [287] [288] peptides were encapsulated in the liposomes as previously described [5] . Peptides were produced by solid phase peptide synthesis using Fmoc-doublecoupling chemistry with a Symphony peptide synthesizer (Protein Tecnologies Inc., Tucson, AZ, USA). Lewis X (Elicityl, Crolles, France) or anti-DC-SIGN antibody coupling to the liposomes was done using thiol-maleimide chemistry. To this end, a thiol group was incorporated to the glycans through derivatization of the glycans with cysteamine (Sigma-Aldrich, St. Louis, USA) and the antibodies with N-succinimidyl S-acetylacetate (Thermo Scientific, Waltham, MA, USA). Briefly, lyophilized glycans were dissolved in dimethyl sulfoxide/acetic acid (8:2) and to this solution 10 equivalents (eq.) of cysteamine were added. After reacting at 65°C for 20 min, 20 eq. of 2-picoline-borane (SigmaAldrich) were added and the mixture was stirred for 2 h at 65°C, followed by purification by normal phase HPLC on a Zorbax-NH 2 prep column (Agilent; elution water/acetonitrile, gradient 85% to 15% of acetonitrile in 30 min). After lyophilization of the collected fractions, the resulting dry powder was dissolved in water and treated with 20 eq. of tris(2-carboxyethyl)phosphine (TCEP, Sigma-Aldrich). After 1 h, the thio-glycan solution was purified using disposable sephadex G10 columns equilibrated with 50 mM ammonium formate (Sigma-Aldrich). Glycan derivatization was confirmed by ESI-MS (Thermo Finnigan LCQ-Deca XP Iontrap mass spectrometer in positive mode using a nanospray capillary needle). Antibodies were dissolved in hepes buffer and 8 eq. of N-succinimidyl S-acetylacetate dissolved in a minimum amount of dimethyl formamide were added. After 45 min at room temperature the
+ dermal dendritic cells results in enhanced CD8 + T cell responses protein was washed 3 times over Vivaspin filters (10kDa cut-off, Sartorius, Goettingen, Germany) and then the acetyl group of N-succinimidyl S-acetylacetate was removed by reaction with a 1:10 solution of hydroxylamine (Sigma-Aldrich) for 1 h. Subsequently, the yielded thio-glycans or thio-antibodies were coupled to the liposomes through a thiol-ene reaction with maleimide groups of the 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine-N-[4-(p-maleimidophenyl) butyramide] lipid. 0.1% of the fluorescent lipophilic dye 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate Salt (DiD; Invitrogen) was added to the liposome preparation to allow visualization after uptake by cells using flow cytometry.
Detection of glycans using ELISA
The conjugation of Le X to the liposomes was confirmed by ELISA using anti-Le X antibodies (Calbiochem, Damstadt, Germany) and correct orientation of the glycans was assessed using DC-SIGN-Fc molecules as previously described [5] . Briefly, liposomes were coated onto NUNC maxisorb plates (Roskilde, Denmark) and incubated o/n at 4 °C. Plates were blocked with 1% BSA in PBS to avoid non-specific binding. After extensive washing, the liposomes were incubated with anti-Le X antibodies or DC-SIGN-Fc for 1.5 h at RT. Binding was detected using a peroxidaselabeled F(ab′)2 goat anti-mouse IgG/Fcγ specific antibody or an F(ab′)2 goat antihuman IgG/Fcγ specific antibody, respectively. The reaction was developed and optical density was measured at 450 nm. As a positive control, Le X attached to polyacrylamide (PAA) (Lectinity, Russia) was used.
Liposome internalization by human moDCs
Human immature moDCs were generated and cultured as previously described [5] . Liposomal uptake was analyzed by FACS following 3 h of incubation at 37°C. When indicated, 20 μg/ml of neutralizing antibodies against DC-SIGN [30] , MR (clone 19.3, BD Biosciences), MGL (clone 125A10.03, Dendritics), DCIR (clone 111F8.o4, Dendritics) or langerin [31] were added.
Liposome internalization via DC-SIGN by human skin DC subsets
Liposomes were diluted in serum-free medium (IMDM) and injected intradermally as described previously [21] . When indicated, 0.4 µg of neutralizing αDC-SIGN antibody (AZN-D1) was co-injected per biopsy. Biopsies were taken after injection using a 6 mm biopsy punch (Microtek, Zutphen, The Netherlands) and cultured in a 48 wells plate containing 1 ml of IMDM supplemented with 10% FCS, 10 μg/ml gentamycin, penicillin and L-glutamine for 48 h, 37°C, 5% CO 2 . After 48 h of culture, the biopsies were discarded, emigrated DCs were harvested and DC-SIGN-mediated internalization of DiD + liposomes was measured using flow cytometry.
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Antigen presentation to human MART-1 specific or GP100 specific CD8 + T cell clone An HLA-A2 restricted CD8 + T cell clone specific for MART-1 [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was generated and cultured as described previously [32] , as well as the GP100 specific CD8 + T cell clone [33] . Indicated concentrations of liposomes resuspended in medium containing GM/4 were intradermally injected in the human skin in the presence or absence of 20 μg/ml neutralizing antibody against DC-SIGN (AZN-D1). After 2 days, emigrated HLA-A2 + skin cells were harvested and 2x10 4 cells/well were seeded in a 96-wells round bottom plate. After extensive washing, MART-1 specific or GP100 specific CD8 + T cells (10 5 /well) were added. After 24 h, supernatants were taken and IFN-γ levels were measured by sandwich ELISA using specific antibody pairs from Biosource (San Diego, CA, USA).
Statistical analysis
Results were analyzed using a one-way ANOVA followed by Bonferrroni Multiple Comparison test. When stated, the two-way ANOVA was performed using GraphPad Prism software (GraphPad Software, San Diego, CA). Results were considered to be significantly different when p<0.05.*p<0.05, **P<0.01, ***p<0.001.
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In-situ delivery of antigen to DC-SIGN αDC-SIGN Figure S1 . Internalization of modified liposomes by monocyte-derived DCs. Uptake of modified DID-labeled liposomes by moDCs is measured using flow cytometry after 3h of incubation. The numbers in the upper right corner depict percentages of DID+ DCs. Data shown depict a representative experiment. N=4
S1
Chapter 3 . Gating strategy after MACS-isolation of dDC subsets. Dermal DCs were allowed to migrate out of the skin for 2 days, whereafter cells were harvasted and CD14+ dDCs were isolated using CD14 microbeads. Flow-through, containing the CD1a+ dDCs was collected and CD1a+ dDCs were subsequently enriched using CD1a+ microbeads. After MACS-isolated, purity of the cells was analyzed using flow cytometry. . CCR7 expression on MACS-isolated skin DC subsets. Dermal DCs and LCs were allowed to migrate out of dermal and epidermal sheets for 2 days. Cells migrated from the dermis were harvasted and CD14+ dDCs were isolated using CD14 microbeads. Flow-through, containing the CD1a+ dDCs was collected and CD1a+ dDCs were subsequently enriched using CD1a+ microbeads. LCs migrated from the epidermis were isolated using CD1a microbeads. Subsequently, CCR7 expression was analyzed on the purified subsets using flow cytometry. Numbers in the graphs depict mean fluorescence intensity of CCR7 of a representative experiment. Data from one representative experiment are shown, n=3. . CD1a+ and CD14+ dDCs show similar capacities to present antigens to CD8+ T cells. Dermal DCs were allowed to migrate out of dermal sheets for 2 days. Cells migrated from the dermis were harvasted and CD14+ dDCs were isolated using CD14 microbeads. Flow-through, containing the CD1a+ dDCs was collected and CD1a+ dDCs were subsequently enriched using CD1a+ microbeads. Subsequently, cells were loaded with the 9 aa Gp100 peptides for 3 h, washed and co-cultured with the Gp100 CD8+ T cell clone. After 24 h, IFN-y was analyzed as measure for T cell activation. N=3, each experiment performed in triplicate. Means ± SEM are depicted.
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